AbCellera Biologics (ABCL) is back in focus after announcing a preclinical collaboration with Jazz Pharmaceuticals. The partnership aims to discover next generation T cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.

The Jazz collaboration press release coincides with sharp share price momentum for AbCellera Biologics, with a 1 day share price return of 10.03% and a 7 day gain of 44.23%. That short term surge sits within a 90 day share price return of 131.34% and a 1 year total shareholder return of 132.66%, signalling strong recent momentum despite a 5 year total shareholder return that remains down 58.61%.

If this kind of oncology focused partnership has caught your attention, it could be a good moment to widen your watchlist with other healthcare AI opportunities using the 41 healthcare AI stocks

With AbCellera Biologics up 132.66% over the past year and the Jazz deal adding fresh excitement, the key question now is whether the recent price action leaves meaningful upside or if the stock already reflects future growth.

Most Popular Narrative: 22.1% Undervalued

With AbCellera Biologics last closing at $8.12 against a narrative fair value of $10.43, the current analyst storyline points to a meaningful valuation gap.

The initiation of Phase I clinical trials for ABCL635 and ABCL575, with promising differentiation factors such as a unique dosing regimen and improved safety profile for ABCL635, is expected to position the company to capture a significant market opportunity in an underserved area, potentially boosting future revenue.

Analysts are not just focusing on science headlines. Their narrative leans on a specific mix of projected revenue trends, margin shifts and a premium earnings multiple that few early stage biotechs see, tied to a detailed forecast curve.

Result: Fair Value of $10.43 (UNDERVALUED)

However, AbCellera Biologics still faces clear hurdles, with widening quarterly net losses and high R&D spending that could pressure cash if the pipeline or partnerships disappoint expectations.

Another View on AbCellera Biologics Using Sales Multiples

The fair value narrative for AbCellera Biologics suggests upside, but its current P/S of 31.3x tells a very different story. That compares with 10.2x for peers and a fair ratio of just 0.3x, which implies meaningful valuation risk if sentiment or growth expectations cool.

For investors weighing those gaps carefully, it may be worth checking how the numbers stack up in more detail through the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on AbCellera Biologics split between clear risks and genuine rewards, now is a good time to look through the numbers yourself, then weigh the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond AbCellera Biologics?

Before you move on, give yourself an edge by lining up a few more high quality ideas. The right shortlist now can make a big difference later.

• Target potential bargains by scanning companies that combine quality fundamentals with attractive pricing using the 42 high quality undervalued stocks.
• Build a sturdier core for your portfolio by focusing on companies with robust finances through the solid balance sheet and fundamentals stocks screener (48 results).
• Get ahead of the crowd by finding underfollowed opportunities with strong fundamentals using the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.